Open-label randomised clinical trial of pharmacokinetics, efficacy, and tolerability of the fixed-dose artesunate/amodiaquine combination therapy versus both drugs administered separately for treatment of uncomplicated falciparum malaria in Kenya

Drugs for Neglected Diseases initiative (DNDi) (Switzerland)0 个研究点目标入组 50 人开始时间: 2007年8月21日最近更新: 2017年4月24日

适应症

试验速览

暂无简介。

•1. Adults from 18 to 60 years of age; either gender
•2. Presenting with acute uncomplicated falciparum malaria:
•2.1. Oral temperature greater than 37.5°C, or
•2.2. History of fever in the last 24 hours
•3. Positive P. falciparum parasitaemia (greater than 1000 asexual parasites/µL)
•4. Written informed consent

•1. Any other concomitant febrile illness, e.g. upper respiratory tract infection or Ear, Nose and Throat (ENT) infection
•2. Features of severe malaria
•3. Mixed Plasmodium infection

发起方

Drugs for Neglected Diseases initiative (DNDi) (Switzerland)